BMI1 and Hyperglycemia: Targeting the tumor microenvironment of PDAC, the investigators found that hyperglycemia upregulates the Bmi1-UPF1-HK2 signaling pathway, which promotes aerobic glycolysis and lactate production in PC cells and leads to immunosuppression, and that Bmi1 is a new potential therapeutic target for patients with combined diabetes mellitus in PDAC (70).